-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dupilumab is an antibody against interleukin-4 receptor alpha used to treat atopic dermatitis (A.
Patients with AD were enrolled in this randomized, double-blind, placebo-controlled, parallel-group Phase III study conducted from December 2018 to February 2020 to receive dubilumab (300 mg) or placebo every 2 weeks , for 16 weeks, and followed up for 12 wee.
RESULTS: 165 patients (mean age 30-6 years; 71-5% male patients) were randomly assigned: 82 to receive dupilumab and 83 to receive place.
Taken together, the results of this study suggest that in Chinese adult patients, dupilumab can effectively improve the symptoms and signs of AD with a favorable safety profi.
Original source:
Y Zhao, et .
The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, controlled study
leave a message here